Awaiting development: Guidance and quality standards

Skip to filters Skip to results

Showing 126 to 150 of 304

Type: GuidanceRemove Type: Guidance filter

Guidance and quality standards awaiting development
Title	Type
Inolimomab (Leukotac) for acute Graft versus host disease (aGvHD) after Allo-HSCT [ID3923]	Technology appraisal guidance
Insertion of a Catheter based intravascular microaxial blood pump for acute heart failure	Interventional procedures guidance
Invimestrocel for treating acute ischaemic stroke within 18 to 36 hours of onset TS ID 10190	Technology appraisal guidance
Irbesartan–propagermanium for treating focal segmental glomerulosclerosis in people 12 years and over having an angiotensin II receptor blocker ID 6469	Technology appraisal guidance
Isatuximab in combination as induction therapy for untreated multiple myeloma when an autologous stem cell transplant is suitable TS ID 11949	Technology appraisal guidance
Istradefylline with levodopa for treating motor fluctuations in Parkinson's disease [ID3868]	Technology appraisal guidance
Ixazomib citrate for maintenance treatment of untreated multiple myeloma after autologous stem cell transplant [ID1517]	Technology appraisal guidance
Larotrectinib for treating NTRK fusion-positive solid tumours (MA review of TA630) [ID6292]	Technology appraisal guidance
Lazertinib with amivantamab and platinum-based chemotherapy for EGFR mutation-positive metastatic non-small-cell lung cancer after a tyrosine kinase inhibitor TS ID 11822	Technology appraisal guidance
Leadless cardiac pacemaker implantation for bradyarrhythmias	Interventional procedures guidance
Lenacapavir for HIV pre-exposure prophylaxis in people 16 years and over at risk of infection [ID6495]	Technology appraisal guidance
Lenvatinib with pembrolizumab and transarterial chemoembolization for untreated localised hepatocellular carcinoma [ID5117]	Technology appraisal guidance
Leriglitazone for treating X-linked andrenoleukodystrophy TS ID 9996	Technology appraisal guidance
Letermovir for preventing cytomegalovirus infection in people under 18 years after allogeneic haematopoietic stem cell transplant TS ID 11868	Technology appraisal guidance
Letetresgene autoleucel for treating NY-ESO-1 advanced unresectable synovial sarcoma in people aged 10 and over or NY-ESO-1 advanced unresectable myxoid round cell liposarcoma in adults TS ID 10652	Technology appraisal guidance
Linerixibat for treating pruritus in people with primary biliary cholangitis [ID6265]	Technology appraisal guidance
Liposomal cytarabine–daunorubicin for treating relapsed or refractory acute myeloid leukaemia in people aged 1 to 21 years [ID4017]	Technology appraisal guidance
Lisocabtagene maraleucel for treating relapsed or refractory aggressive B-cell non-Hodgkin lymphoma after 1 systemic treatment [ID3869]	Technology appraisal guidance
Low-energy contact X-ray brachytherapy (the Papillon technique) for locally advanced rectal cancer	Interventional procedures guidance
Lurbinectedin with atezolizumab for maintenance treatment of extensive-stage small-cell lung cancer TS ID 11970	Technology appraisal guidance
Luspatercept for treating anaemia in non-transfusion dependent beta-thalassaemia [ID3870]	Technology appraisal guidance
Lutetium oxodotreotide with octreotide for newly diagnosed unresectable or metastatic gastroenteropancreatic neuroendocrine tumours [ID6315]	Technology appraisal guidance
LY3209590 for treating type 1 diabetes in people on multiple daily insulin injections [ID6498]	Technology appraisal guidance
LY3209590 for treating type 2 diabetes in people on daily insulin injections [ID6499]	Technology appraisal guidance
Masitinib with riluzole for treating amyotrophic lateral sclerosis TS ID 10728	Technology appraisal guidance

Results per page

10
25
50
All